Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954263 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
A Phase 1 study of Healthy Adults, Elderly Subjects, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02954263 is a Phase 1 study of Healthy Adults, Elderly Subjects that has completed, run by Theravance Biopharma. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02954263, a Phase 1 study of Healthy Adults, Elderly Subjects, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-1439
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954263
The ClinicalTrials.gov registry entry for NCT02954263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adults, Elderly Subjects appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02954263 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT02954263 about?
NCT02954263 is a clinical study titled "Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects". Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects
What is the current status of trial NCT02954263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-11. Estimated completion is 2017-04.
What conditions does trial NCT02954263 study?
This clinical trial studies the following conditions: Healthy Adults, Elderly Subjects.
What interventions are being tested in trial NCT02954263?
The interventions under investigation include: Placebo (DRUG), TD-1439 (DRUG).
Who is sponsoring clinical trial NCT02954263?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02954263 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults, Elderly Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.